Literature DB >> 4023479

Comparative analysis of two rates.

O Miettinen, M Nurminen.   

Abstract

In this paper, we examine comparative analysis of rates with a view to each of the usual comparative parameters-rate difference (RD), rate ratio (RR) and odds ratio (OR)-and with particular reference to first principles. For RD and RR we show the prevailing statistical practices to be rather poor. We stress the need for restricted estimation of variance in the chi-square function underlying interval estimation (and also point estimation and hypothesis testing). For RR analysis we propose a chi-square formulation analogous to that for RD and, thus, one which obviates the present practice of log transformation and its associated use of Taylor series approximation of the variance. As for OR analysis, we emphasize that the chi-square function, introduced by Cornfield for unstratified data, and extended by Gart to the case of stratified analysis, is based on the efficient score and thus embodies its optimality properties. We provide simulation results to evince the better performance of the proposed (parameter-constrained) procedures over the traditional ones.

Entities:  

Mesh:

Year:  1985        PMID: 4023479     DOI: 10.1002/sim.4780040211

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  200 in total

1.  Profile Likelihood and Incomplete Data.

Authors:  Zhiwei Zhang
Journal:  Int Stat Rev       Date:  2010-04-01       Impact factor: 2.217

2.  Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Authors:  W Joseph Herring; Kathleen M Connor; Ellen Snyder; Duane B Snavely; Ying Zhang; Jill Hutzelmann; Deborah Matzura-Wolfe; Ruth M Benca; Andrew D Krystal; James K Walsh; Christopher Lines; Thomas Roth; David Michelson
Journal:  J Clin Sleep Med       Date:  2016-09-15       Impact factor: 4.062

3.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

4.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Authors:  H David Friedland; Tanya O'Neal; Donald Biek; Paul B Eckburg; Douglas R Rank; Lily Llorens; Alex Smith; Gary W Witherell; Joseph B Laudano; Dirk Thye
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

6.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

7.  Stroke seasonality associations with subtype, etiology and laboratory results in the Ludwigshafen Stroke Study (LuSSt).

Authors:  Frederick Palm; Michael Dos Santos; Christian Urbanek; Matthias Greulich; Kathrin Zimmer; Anton Safer; Armin Jürgen Grau; Heiko Becher
Journal:  Eur J Epidemiol       Date:  2013-02-06       Impact factor: 8.082

8.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.

Authors:  Keith S Kaye; Helen W Boucher; Michelle L Brown; Angela Aggrey; Ireen Khan; Hee-Koung Joeng; Robert W Tipping; Jiejun Du; Katherine Young; Joan R Butterton; Amanda Paschke
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Paediatric trauma and trauma care in Flanders (Belgium). Methodology and first descriptive results of the PENTA registry.

Authors:  Patrick Van de Voorde; Marc Sabbe; Paul Calle; Emmanuel Lesaffre; Dimitris Rizopoulos; Roula Tsonaka; Daphne Christiaens; Anneleen Vantomme; Annick De Jaeger; Dirk Matthys
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.